{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:28:35Z","timestamp":1761532115133,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.brachy.2021.11.006","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:07:07Z","timestamp":1645441627000},"page":"216-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["MRI-defined treatment margins, urinary toxicity, and PSA response in LDR prostate brachytherapy"],"prefix":"10.1016","volume":"21","author":[{"given":"Jim N","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-3318","authenticated-orcid":false,"given":"Juanita M","family":"Crook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2021.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/cncr.27911","article-title":"Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate risk prostate cancer","volume":"119","author":"Morris","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.brachy.2021.11.006_bib0002","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2010.04.038","article-title":"10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1 100 patients","volume":"80","author":"Crook","year":"2011","journal-title":"Int. J. Radiation Oncology Biol. Phys."},{"key":"10.1016\/j.brachy.2021.11.006_bib0003","unstructured":"Morris J.W., Tyldesley S., Pai H., et al. ASCENDE-RT: a multi-center, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachtherapy (LDR-B) for men with unfavourable-risk localized prostate cancer."},{"issue":"13","key":"10.1016\/j.brachy.2021.11.006_bib0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.brachy.2013.08.006","article-title":"Whole prostate D90 and V100: a dose-response analysis of 2000 consecutive 125I monotherapy patients","author":"Morris","year":"2014","journal-title":"Brachytherapy"},{"issue":"5","key":"10.1016\/j.brachy.2021.11.006_bib0005","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ijrobp.2007.05.002","article-title":"Customized dose prescription for permanent prostate brachytherapy: insights from a multicentre analysis of dosimetry outcomes","volume":"69","author":"Stone","year":"2007","journal-title":"Int. J. Radiation oncology Biol. Phys."},{"key":"10.1016\/j.brachy.2021.11.006_bib0006","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00130404-200311000-00004","article-title":"Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery","volume":"9","author":"Teh","year":"2003","journal-title":"Cancer Journal"},{"issue":"4","key":"10.1016\/j.brachy.2021.11.006_bib0007","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2006.02.039","article-title":"Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posteriolaterally to account for microscopic extension?","volume":"65","author":"Chao","year":"2006","journal-title":"Int J Radiation Oncology Biol Phys"},{"issue":"3","key":"10.1016\/j.brachy.2021.11.006_bib0008","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0090-4295(99)00458-6","article-title":"Extent of extracapsular extension in localized prostate cancer","volume":"55","author":"Sohayada","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2021.11.006_bib0009","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2630::AID-CNCR20>3.0.CO;2-L","volume":"85","author":"Davis","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.brachy.2021.11.006_bib0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ijrobp.2009.06.040","article-title":"Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy","volume":"77","author":"Crook","year":"2010","journal-title":"Int J Radiation Oncology Biol Phys"},{"issue":"2","key":"10.1016\/j.brachy.2021.11.006_bib0011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"10.1016\/j.brachy.2021.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ijrobp.2008.07.042","article-title":"Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer","volume":"73","author":"Morris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.11.006_bib0013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brachy.2012.03.001","article-title":"Defining a magnetic resonance scan sequence for permanent seed prostate brachytherapy postimplant assessment","volume":"12","author":"Bowes","year":"2013","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.brachy.2021.11.006_bib0014","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0360-3016(01)01811-9","article-title":"The dosimetry of prostate brachytherapy-induced urethral strictures","volume":"52","author":"Merrick","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.brachy.2021.11.006_bib0015","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(05)00681-6","article-title":"Risk factors for the development of prostate brachytherapy related urethral strictures","volume":"175","author":"Merrick","year":"2006","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.brachy.2021.11.006_bib0016","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.brachy.2013.04.003","article-title":"Regional treatment margins for prostate brachytherapy","volume":"12","author":"Jastaniyah","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.11.006_bib0017","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brachy.2013.08.003","article-title":"Multisector prostate dosimetric quality: analysis of a large community database","volume":"13","author":"Merrick","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.11.006_bib0018","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.brachy.2014.12.004","article-title":"Regional dose metrics as predictors of biochemical recurrence after low-dose-rate prostate brachytherapy","volume":"14","author":"Spadinger","year":"2015","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.brachy.2021.11.006_bib0019","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.brachy.2021.11.006_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00130404-200405000-00007","article-title":"Treatment margins predict biochemical outcomes after prostate brachytherapy","volume":"10","author":"Choi","year":"2004","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.brachy.2021.11.006_bib0021","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/21681805.2018.1484509","article-title":"The measurement of membranous urethral length using transperineal ultrasound prior to radical prostatectomy","volume":"52","author":"Mungovan","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.brachy.2021.11.006_bib0022","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121005365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121005365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:16:58Z","timestamp":1761531418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472121005365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1538472121005365"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2021.11.006","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRI-defined treatment margins, urinary toxicity, and PSA response in LDR prostate brachytherapy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}